Long-Term Results of a Phase II Trial of Induction Paclitaxel-Carboplatin Followed by Concurrent Radiation Therapy and Weekly Paclitaxel and Consolidation Paclitaxel-Carboplatin in Stage III Non-small Cell Lung Cancer  by Casas, Francesc et al.
ORIGINAL ARTICLE
Long-Term Results of a Phase II Trial of Induction Paclitaxel-
Carboplatin Followed by Concurrent Radiation Therapy
and Weekly Paclitaxel and Consolidation Paclitaxel-
Carboplatin in Stage III Non-small Cell Lung Cancer
Francesc Casas, PhD,* Núria Viñolas, MD,† Ferran Ferrer, MD,‡ Carles Agustı´, MD,§ Marcelo Sanchez, MD,
Josep Maria Gimferrer, MD,¶ Francisco Lomeña, MD,# Marc Campayo, PhD,† and Branislav Jeremic, MD‡
Introduction: Long-term results of a phase II study on the use of
induction chemotherapy (CHT) using paclitaxel (P)-carboplatin (C)
followed by a concurrent radiation therapy (RT) and weekly P and
consolidation PC were reviewed.
Patients and Methods: Thirty-two patients with stage III non-small
cell lung cancer started treatment with induction CHT (two cycles of
P 175 mg/m2, day 1 and C, area under the curve 6, day 1, given at
3-week interval), after which accelerated RT with a concomitant
boost (“field-in-a-field”) (1.8 Gy large fields and the boost dose 0.88
Gy) was administered in 23 fractions with 61.64 Gy and concurrent
weekly P (45 mg/m2). Consolidation with two cycles of PC was
administered.
Results: The median follow-up for all 32 patients was 17.2 months
(range, 3.8–107 months). The median survival time was 16.9
months, and the 5-year survival and 10-year survival were 25% and
17.5%, respectively. The median time for disease progression was
9.5 months, and disease-free survival was 21% at 5 and 10 years.
The median time to local progression was 14.6 months, and the 5- to
10-year local progression-free survival was 35.7%. The median time
to distant metastasis was 17.5 months. Toxicity was acceptable, with
only one (3.1%) patient experiencing grade 5 (lung) toxicity and
another patient presenting grade 4 toxicity (leucopenia).
Conclusions: The results of this single-institutional phase II study
of induction CHT followed by concurrent RT-CHT and consolida-
tion CHT in very unfavorable patient population showed acceptable
results with acceptable toxicity.
Key Words: Accelerated radiotherapy, Concomitant boost, Che-
motherapy, Non-small cell lung cancer, Stage III, Concurrent
radiochemotherapy.
(J Thorac Oncol. 2011;6: 79–85)
Radiochemotherapy (RT-CHT) is currently a recom-mended treatment approach for locally advanced inoper-
able stage IIIA and stage IIIB non-small cell lung cancer
(NSCLC) in patients with good performance status (PS,
0–1).1 A concurrent approach has been shown to be superior
to sequential treatment delivery in the meta-analyses in terms
of longer survival.2
In 2004, we published our experience3 combining full-
dose induction CH (cisplatin plus gemcitabine for two cycles)
followed by concurrent administration of accelerated radio-
therapy with a concomitant boost (with a total dose of 61.64
Gy administered in 23 fractions), with cisplatin and navelbine
for two courses, finally followed by two courses of the same
initial chemotherapy (CHT). The median survival was 15.4
months with an actuarial 1-, 2- and 3-year survival of 67, 21
and 15%, respectively. Hematological and esophageal toxic-
ity  grade 3 was not negligible (60% and 30%, respec-
tively). The RT schedule consisted of an accelerated schedule
using the concomitant boost technique.4 This was achieved
using a “field-in-a-field” technique (simultaneously inte-
grated boost), whereby the larger area was treated to 1.8 Gy
followed by a smaller area (boost) being treated with an
additional 0.88 Gy with no time delay.
Preliminary reports of a phase I/II study by Uitterhoeve et
al.,5 which combined a daily low-dose CHT and a similar
accelerated RT schedule, obtained an encouraging overall actu-
arial 1- and 2-year survival of 53% and 40%, respectively.
With this background, our aim was to make a new
phase II trial to assess the safety, activity, survival, and
progression-free survival after full-dose induction CH, con-
current RT-CHT based on accelerated RT with weekly pac-
litaxel (P), and full-dose consolidation CHT as induction
therapy. Our hypothesis was that this phase II would reduce
toxicity maintaining at least the same effectiveness as our
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previous experience. The primary objective was to estimate
the efficacy and safety of a different RT-CHT scheme.
We present herewith the long-term results of our single-
institutional phase II trial that included most of the patients
considered as “poor-risk” and, therefore, suitable for this
intensive treatment.
PATIENTS AND METHODS
A phase II study on combined RT-CHT in patients with
locally advanced NSCLC was undertaken from 2000 to 2003.
Patients were staged using the 1997 International Staging
System, Tumor Nodes Metastasis Classification. The inclu-
sion criteria were adult patients (18–80 years) and Eastern
Cooperative Oncology Group status 0 to 2, minimum pulmo-
nary function of 1 liter with histologic or cytologic proof of
NSCLC. Patients with pleural effusions were excluded. En-
doscopic esophageal ultrasound was available during the
study period. Endoscopic esophageal ultrasound, mediasti-
noscopy, or direct function of supraclavicular nodes was
made to confirm N3 involvement (100%). The tumor and
nodes had to be unresectable at the time of diagnosis as
evaluated by a multidisciplinary Lung Cancer Committee of
experienced radiologists, thoracic surgeons, radiation oncolo-
gists, medical oncologist, and pneumologists. Patients had to
be in a satisfactory medical condition to undergo CHT and
thoracic radiotherapy (Karnosfky Performance Status
70%). Active supportive treatment was provided to PS 1 to
2 patients with dietetic and hematopoietic tools including
erythropoietin.6 In a previously published trial, a total of 51
patients with lung cancer were enrolled in a prospective phase
II protocol in Hospital Clínic between September 1996 and
September 2000. After neoadjuvant CHT based on cisplatin,
an hemoglobin level of less than 11 g/dl was required (ac-
cording to Catalonian Erythropoietin Committee law restric-
tions) to receive erythropoietin (150 IU/KG, 3 times weekly)
with oral iron (600 mg/d) for a maximum of 8 weeks to
maintain the levels of hemoglobin and the Karnofsky index.
After the good results obtained, this protocol was imple-
mented as the habitual clinical practice in our hospital.
Our study was approved by the institutional Ethics
Committee, and all patients gave informed consent.
Pretreatment diagnostic aspects included clinical exam-
ination, full laboratory/biochemistry and blood tests, com-
puted tomography (CT) scan of the thorax and upper abdo-
men, and bronchoscopy. Brain imaging or bone scan was not
done in the absence of symptoms. PET-CT was not done in
this group because it was not allowed for staging in Spain
during the study period. We used the Helax TMS 6.1B
planning system for three-dimensional (3D) planning. This
system corrects for lung density by pencil beam algorithm.
Treatment started with two cycles of induction CHT
consisting of P 175 mg/m2, day 1 and carboplatin (C), area
under the curve 6, day 1, given at a 3-week interval. Three
weeks after the end of the second PC, patients started an RT
schedule that consisted of an accelerated schedule using the
concomitant boost technique. Patients received 61.64 Gy
using 3D conformal RT over a total of 5 weeks (23 treatment
days). For the initial larger area, the clinical target volume
(CTV) was derived from GTV (primary tumor and lymph
nodes of1 cm at the largest diameter as seen in the planning
CT scan) by expanding 0.5 cm in all directions to include
microscopic involvement. Finally, we expanded the CTV by
1 cm to create the planning target volume (PTV). Elective
nodal irradiation (ENI), defined as prophylactic irradiation of
uninvolved mediastinal nodes following CT scan informa-
tion, was used in this field but only limited to first uninvolved
lymphatic level. In the boost field, GTV was equivalent to
CTV, and 1 cm was added to create the PTV. In the boost
field, only macroscopic disease (primary tumor plus nodal
areas) was considered as CTV, and any type of ENI was
omitted. The dose was calculated following ICRU recom-
mendations. V20 constraints were not applied in this protocol
as their use was initiated in our department in 2003. The total
dose and the number of the fractions were chosen after a
previous dosimetric study to maintain a safe dose of approx-
imately 45 Gy at the spinal cord level. In the original study of
reference of concomitant boost techniques by Graham et al.,4
the total dose and number of fractions were 75.04 Gy and 28,
respectively, although the boost area included the primary
tumor only instead of the tumor and nodes more than 1 cm
that we used.
During the RT course, P was given at a weekly dose of
45 mg/m2. Three weeks after the end of concurrent RT-CHT,
patients continued with the same PC with two cycles planned
at a 3-week interval.
Patients were evaluated for response after the second
cycle of consolidation PC using thoracic and upper abdomi-
nal CT according to the RECIST criteria.7 Patients were
followed at regular time intervals that included three monthly
clinical examination, laboratory and biochemistry analysis,
and CT scans of the thorax. Additional tests were performed
if clinically indicated. PET-CT was not allowed for follow-up
in our country during the period of study. Systematic bron-
choscopy or biopsies at the time of regular follow-up visit or
at the time of suspected progression was not performed.
Toxicity was scored using the WHO criteria8 but was con-
verted into CTCAE v2.0.
Statistical Analysis
Sample size considerations were based on expected
hematological toxicity grade 3 or higher. Based on previous
experience (Ref. 3), an objective decrease in hematological
toxicity of 20% was assumed. Accepting an alpha risk of 0.1
and a beta risk of 0.20 in a one-sided test, approximately 30
patients were needed with a drop-out rate of 0.05. Statistical
analysis was done using the SPSS version 14 software pack-
age. Statistical analysis was performed by intention to treat.
The quantitative characteristics of the patients have been
described using median values and interquartile ranges, and
qualitative characteristics using proportions. The Fisher’s
exact test was used to examine the association between
different measures. A binomial distribution was assumed to
estimate the 95% confidence interval of the relative frequency
to be in complete response, partial response, stable disease, or
progression. Survival analysis was estimated using the
Kaplan–Meier method. The Cox proportional hazard regres-
sion model was used to evaluate the effect of explanatory
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variables on survival time. Factors that were statistically
significant in the univariate analysis at a 90% confidence
level were added in a stepwise manner to the multivariate
model. All p values were based on two-sided testing with a
95% confidence level. All statistical analyses were done by
one of the authors (F.F.).
RESULTS
A total of 32 patients were enrolled in this phase II
study. No patient was lost to follow-up. The median fol-
low-up for all 32 patients was 17.2 months (range, 3.8–107
months). The median follow-up for the 27 patients who died
was 12.7 months (range, 3.8–94.1 months). Patient and tumor
characteristics are listed in Table 1. Most of the patients were
staged as IIIB, and all but one (3.1%) were smokers. More
than 80% of the patients were with PS 1 to 2. Almost 85% of
patients were staged T3–4 (nonmalignant pleural or cardiac
effusion), and more than 70% patients were N 2–3, repre-
senting a “poor-risk” category (Table 1).
All patients received two planned induction CHT cy-
cles of PC and proceeded with concurrent RT-CHT. One
patient developed brain hemorrhage after four RT fractions
and discontinued the treatment. Another patient stopped the
concurrent part due to the development of brain metastasis
(after 8 Gy to primary tumor) and was subsequently given
palliative brain RT. Both patients were followed up until death
and included in the survival analysis. No other patient experi-
enced distant progression until the end of concurrent RT-CHT.
Therefore, a total of 30 patients finished concurrent RT-CHT
part of the treatment. Weekly P dosing was given six times
during the radiation therapy (RT) in 16 patients (50%), five
times in six patients (18.8%), four times in five patients
(15.6%), thrice in one patient (3.1%), and twice in two
patients (6.3%), whereas one patient did not receive weekly P
and received only induction CHT. One patient was treated
over 7 weeks of RT and, therefore, received a total of 7
weekly doses of P. The protocol required weekly P to begin
after 21 days of the second cycle of C-P. RT was begun in the
same week as the first P (to be given weekly during the RT
course); however, because of various reasons (waiting list,
holidays, and machine repair), some patients did not receive
the first dose of weekly P concurrently with RT, starting
several days later. Depending on the day of the week, the
patient began RT, four to six cycles were administered during
concurrent RT-CHT. A total of 27 patients (84.4%) received
this planned intensity.
Consolidation PC (one cycle) was given to 25 patients,
and only seven patients received both planned cycles of CHT
due to diminution of PS following the criteria of the medical
oncologist (N.V.).
Response to treatment was evaluated at the end of the
planned consolidation phase of the treatment. The overall
response rate (Table 2) was 72%, whereas both stable
disease and progressive disease were observed (12.5%
each), not being evaluated in one patient who developed a
brain hemorrhage.
The median survival time for all 32 patients was 16.9
months, and the 5- to 10-year survival was 25% and 17.5%,
respectively (Figure 1).
The median time for disease progression was 9.5
months with a disease-free survival of 21% at 5 and 8 years
(Figure 2).
The median time to local progression was 14.6 months,
and the 5- to 10-year local progression-free survival was
35.7% (Figure 3). The median time to distant metastasis was
17.5 months, and the 5- to 10-year distant metastasis-free
survival was 41. 4% (Figure 4).
We did not find any breakdown in patient outcome
according to T and N status. The surviving patients were
staged as T4 N1, T3 N2, T4 N2, T2 N3, and T4 N1 with a
survival of 74, 74, 85.66, 92.37, 99.47, and 106.97 months,
respectively.
Patterns of failure identified local progression alone in
eight patients (25%), distant progression alone in seven
patients (22%), whereas both local progression and distant
TABLE 1. Patients and Tumor Characteristics (N  32)
Age
Mean, 61 yr
(39–77)
Median, 64 yr
n Percentage
Sex Women 4 12.5
Men 28 87.5
Smoking habit No 1 3.1
Yes 50 p-year 17 53.3
Yes 50 p-year 14 43.7
PS 0 6 18.8
1 23 71.9
2 3 9.4
Weight loss Yes 7 21.9
No 25 78.1
Stage IIIA 3 9.4
IIIB 29 90.6
T 2 5 15.6
3 5 15.6
4 22 68.8
N 0 5 15.6
1 4 12.5
2 13 40.6
3 10 31.3
Pathology Non-small cell 5 15.6
Adenocarcinoma 17 53.1
Squamous 9 28.1
Large Cell 1 3.1
PS, performance status.
TABLE 2. RT-CHT Response
Response (n  31) N Percentage
Complete 3 9.4
Partial 20 62.5
Stabilization 4 12.5
Progression 4 12.5
Not evaluated 1 3.1
RT, radiation therapy; CHT, chemotherapy.
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progression were observed in six patients (19%). Of the 11
(34%) nonprogression patients, tumor progression could not
be evaluated in only one (3%) patient (with brain hemor-
rhage). In the remaining 10 (31%) patients, progression was
not observed. Causes of death included lung cancer progres-
sion in 21 (66%), being cancer-unrelated in five (16%)
patients: large bowel perforation (n  1), brain hemorrhage
(n 1), second or third primary tumor with or without distant
metastasis (n  2), and sudden death at home without
previous progression noted on two consecutive follow-up
examinations (n  1). Interestingly, among nonprogression
(of lung cancer) patients, three deaths occurred more than 5
years after the beginning of treatment.
To investigate the influence of potential prognostic
factors (from Table 1), we performed univariate analysis of
these factors. None of the factors investigated influenced
survival, and therefore, multivariate analysis was not done.
The acute toxicity pattern (Table 3) revealed grade 3 to
grade 4 toxicities in a few patients; grade 3 anemia in one
patient (3.1%), leucopenia grades 3 to 4 in two patients
(6.2%), and grade 3 thrombocytopenia in one patient (3.1%).
Grade 2 esophagitis was found in nine patients (28.1%) and
grade 3 in two patients (6.2%) all related to RT-CHT. Only
one (3.1%) patient died of treatment-related lung toxicity
having a T2N3 tumor and being diagnosed with initial idio-
pathic pulmonary fibrosis at the same time and had received
two cycles of induction PC, followed by 61 Gy and 7 weekly
FIGURE 1. Overall survival.
FIGURE 2. Disease-free interval.
FIGURE 3. Local disease-free interval.
FIGURE 4. Distant disease-free interval.
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doses of P and only one cycle of consolidation PC. This
patient died 4.21 months after having begun induction CHT.
In relationship to delayed toxicities in 10 patients fol-
lowed up for more than 5 years, we observed that all the
patients presented toxicity of pneumonitis and/or grade 1
pulmonary infiltrates with radiographic changes, but five
presented grade 2 of dyspnea (on exertion). All these five
patients are being followed up by the pneumologist on the
Committee. No long-term toxicity, dysfunction, or stenosis
were observed at an esophageal level.
DISCUSSION
To explore novel strategies for RT-CHT in advanced
NSNLC stage IIIB and to diminish the toxicity of the com-
bined treatment, we conducted a phase II trial with an
induction phase with full doses CP followed by accelerated
modified scheduling of RT with a concomitant boost concur-
rent with weekly P and finally consolidation CHT with PC.
The eligibility criteria included few patients (n  3)
with PS 2, weight loss more than 10% (n  7), whereas most
(90%) were those with stage IIIB. Despite these poor prog-
nostic features, the median survival was 16.9 months, and the
5-year survival and 10-year survival were 25% and 17.5%,
respectively. These results are similar to the best results of
previous phase III trials of concurrent versus sequential
RT-CHT,9–11 those of the phase III induction CHT and
RT-CHT,12–14 and those of the consolidation CHT therapy
after concurrent RT-CHT.15 The toxicity, albeit significant
(one grade 5), was manageable and was diminished compared
with that of a previous trial,3 thereby confirming our previous
hypothesis.
In the present series, patterns of failure with local
progression alone were identified in 25% of the patients with
both local and distant progression being observed in 19% of
the patients each. These rates show a high local control
despite very locally advanced lung tumors (85% staged T3–4
and 70% patients with N 2–3). No relationship was found
between outcome and T or N status probably due to the small
size of the sample. This good local control could be explained
by the RT schedule (accelerated scheduling with concomitant
boost) used. As indicated previously, the total dose and the
number of the fractions (23 fractions) were chosen after a
previous dosimetric study to maintain a safe dose of approx-
imately 46 Gy at a spinal cord level. The main reason for this
was that a previous study was begun with two-dimensional
tools (in 26 patients) initially using anteroposterior-pos-
teroanterior (AP-PA) fields (large and boost fields consecu-
tively) during 16 fractions maintaining a maximum dose of
43 Gy (42.88 Gy) in the spinal cord, and the last seven
fractions were performed with oblique fields by three slices of
thoracic CT at the tumor level maintaining a total dose of 46
Gy at the level of the spinal cord. In the last part of the
previous study (11 patients), we used 3D planning and
avoided AP-PA fields and used only oblique fields while
maintaining the total number of fractions. This exact number
of fractions (23) was maintained in the present phase II study
following our experience with their safety. The local control
results could probably be improved using more margins to
include all type of uncertainties, and margins of 1 cm to
expand CTV to PTV are not sufficient with 3D planning
without breathing control. Nonetheless, it should be taken
into consideration that our phase II study was conducted
before systematic 3D planning in advanced NSCLC.16
This old technique of concomitant boost17 was adapted
to substitute a real accelerated hyperfractionated RT treat-
ment because this was not possible in our department due to
the existing waiting lists. This technique is currently not
common, but at the time this trial was ongoing, two important
radiation oncologist groups published very promising results
with concomitant boost RT alone18 or in association with
CHT.5
The rationale for accelerated fractionation is that ex-
perimental and clinical experience suggests that acceleration
of the RT course may lead to improved tumor control, likely
by allowing less opportunity for tumor repopulation during
treatment, and has resulted in improved clinical outcomes in
locally advanced NSCLC.19 The continuous hyperfraction-
ated accelerated RT trial with 54 Gy in 36 fractions of 1.5 Gy
over 12 consecutive days demonstrated improved survival
compared with conventional thoracic RT. The Eastern Coop-
erative Oncology Group attempted to test continuous hyper-
fractionated accelerated RT trial, eliminating RT during
weekends (HART) in a phase III trial. Nevertheless, the
HART trial closed early because of slow accrual. The median
survival was 20.3 months for HART compared with 14.9
months with standard RT, but this difference did not reach
statistical significance.20 Nevertheless, the results in the
HART cohort point to the promise of thoracic RT dose
intensity. Finally, in one retrospective trial with 261 patients
with NSCLC, Liao et al.21 also found significantly improved
locoregional control with accelerated RT.
Despite the high intensity of our protocol, the toxicity
observed compares favorably with studies of concurrent RT-
CHT given alone or with induction CHT followed by con-
current RT-CHT and consolidation CHT. This is probably
based on the radiosensitizing action of weekly P, which
improves the local action of RT without increasing the
hematological toxicity of CHT as shown in pivotal trials
TABLE 3. RT-CHT Acute Toxicitya
Grade of
Toxicity 0 1 2 3 4 5
Anemia 27 (84.4) 2 (6.3) 2 (6.3) 1 (3.1) 0 0
Luecopenia 29 (90.6) 0 1 (3.1) 1 (3.1) 1 (3.1) 0
Plaquetopenia 31 (96.9) 0 0 1 (3.1) 0 0
Hepatic 29 (90.6) 1 (3.1) 2 (6.3) 0 0 0
Mucositis 11 (34.4) 10 (31.3) 9 (28.1) 2 (6.2) 0 0
Emesis 23 (71.9) 3 (9.4) 5 (15.6) 1 (3.1) 0 0
Fever 5 (15.6) 19 (59.4) 0 0 0
Alopecia 19 (59.4) 2 (6.3) 5 (15.7) 0 0 0
Neurologic 23 (71.9) 5 (15.6) 3 (9.4) 0 0 0
Astheia 16 (50.0) 6 (18.8) 5 (15.6) 5 (15.6) 0 0
Dyspnea 28 (87.5) 3 (9.4) 0 0 1 (3.1)
a Toxicity attributed to CHT and/or RT.
RT, radiation therapy; CHT, chemotherapy.
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using protacted low-dose CHT (platinum-based in both cases)
described by Schaake-Koning et al.22 and Jeremic et al.23
Regarding the low incidence of esophageal toxicity reported
in this study, since the beginning of the use of concurrent
RT-CHT in 1994, a close relationship has been observed
between leucopenia grades 3 to 4 and esophageal toxicity
(grades 2–3), as summarized previously.24 In this context, the
low incidence of important leucopenia (grades 3–4 was
6.2%) in our trial may have a direct relationship with esoph-
agitis grade 3 (6.2%).
This improvement in local control could also explain
the long-term survival by diminishing it as a potential source
of distant progression in this very unfavorable prognostic
population. It is important to point out that survival was
almost the same from 5 to 10 years (22% throughout the
period) with 3 deaths after 5 years of the first lung cancer
treatment for non-NSCLC-related causes (including two sec-
ond malignancies).
Our phase II trail was also inspired by the first results
of phase II trial by Gandara et al.,25 which were, however, not
confirmed in a phase III trial. After the Hoosier Oncology
Group negative trial consolidation, CH is not currently con-
sidered as an evidence-based standard of care. Moreover,
based on the studies by Vokes et al.12 and Kim et al.,13 which
directly addressed the issue of induction therapy, it is not
possible to recommend the use of induction CHT before
concurrent RT-CHT in routine clinical practice. A recent and
elegant revision about neoadjuvant cisplatin administration at
different tumor sites (including NSCLC) showed that induc-
tion CHT could activate epidermal growth factor receptor
expression that, in itself, may promote radioresistance and
accelerated repopulation during RT. In the possible cases that
may occur, this overexpression of epidermal growth factor
receptor local control can be improved by accelerated frac-
tionation26 as is the case in our protocol.
It currently seems that only two cycles of CHT given
during RT provide maximum therapeutic effect in stage III.27
Similarly, concurrent RT-CHT might be integrated in a phase
III trial combining accelerated treatment, scheduling RT with
weekly CHT. Since no randomized study has yet compared
accelerated RT and radiosensitizing low dose versus system-
ically active high-dose therapy, it remains unknown whether
either of these two approaches is superior to another. Thus,
the integration of accelerated RT (maybe without ENI) re-
quires further investigation.
Finally, the integration of functional imaging with
FDG-PET for RT treatment planning (available in the Span-
ish Public Health System only since 2005) could aid in
selecting patients who are not appropriate candidates for
radical thoracic RT, secondarily achieving greater local con-
trol and overall survival.
REFERENCES
1. Robinson LA, Ruckdeschel JC, Wagner H Jr, et al. Treatment of
non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical
practice guidelines (2nd Edition). Chest 2007;132(Suppl 3):243S–
265S.
2. Auperin A, Rolland E, Walter C, et al. Concomitant radio-chemo-
therapy (RT-CT) versus sequential RT-CT in locally advanced non-
small cell lung cancer (NSCLC): a meta-analysis using individual
patient data (IPD) from randomised clinical trials. J Thorac Oncol
2007;2:3009S.
3. Reguart N, Vin˜olas N, Casas F, et al. Integrating concurrent navelbine
and cisplatin to hyperfractionated radiotherapy in locally advanced
non-small cell lung cancer patients treated with induction and consoli-
dation chemotherapy: feasibility and activity results. Lung cancer 2004;
45:67–75.
4. Graham MV, Pajak TE, Herskovic AM, et al. Phase I/II study of
treatment of locally advanced (T3/T4) non-oat cell lung cancer with
concomitant boost radiotherapy by the radiation therapy oncology group
(RTOG 83–12): long-term results. J Radiot oncol Biol Phys 1995;31:
819–824.
5. Uitterhoeve ALJ, Belderbos JSA, Koolen MGJ, et al. Toxicity of
high-dose radiotherapy combined with daily cisplatin in non-small cell
lung cancer: results of the EORTC 08912 phase I/II. Eur J Cancer
2000;36:592–600.
6. Casas F, Vin˜olas N, Ferrer F, et al. Improvement in performance status
alters erythropoietin treatment in lung cancer patients undergoing concur-
rent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2003;55:116–124.
7. Therase P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate
the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:
205–216.
8. World Health Organization. World Health Organization Hand Book for
Reporting Results of Cancer Treatment. Publication no. 48. Geneva:
World Health Organization, 1979.
9. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent
versus sequential thoracic radiotherapy in combination with mitomycin,
vindesine, and cisplatin in unresectable stage III non-small-cell lung
cancer. J Clin Oncol 1999;17:2692–2699.
10. Curran WJ, Scott C, Langer CJ, et al. Long-term benefits is observed in
a phase III comparison of sequential vs. concurrent chemo-radiation for
patients with unresectable stage III NSCLC:RTOG 9410 (Abstract
2499). Proc Am Soc Clin Oncol 2003;22:621.
11. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of
sequential chemoradiotherapy compared with concurrent chemoradio-
therapy in locally advanced non-small-cell lung cancer: Groupe Lyon
Saint-Eteinne d’Oncologie Thoracique-Groupe Franc¸ais de PneumoCan-
cerologie NPC 95–01 Study. J Clin Oncol 2005;23:5910–5917.
12. Vokes EE, HernJE, Kelley MJ, et al. Induction chemotherapy followed
by chemoradiotherapy compared with chemoradiotherapy alone for
regionally advanced unresectable stage III non-small cell lung cancer.
Cancer and Leukemia Group B. J Clin Oncol 2007;25:1698–1704.
13. Kim MK, Kim SW, Choi EK, et al. Induction chemotherapy followed by
concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresect-
able stage III non-small cell lung cancer (NSCLC): randomized phase III
trial. J Thorac Oncol 2007;2:3008S.
14. Huber RM, Fklentje M Scmidt M, et al. Simultaneous chemoradiation
compared with radiotherapy alone after induction chemotherapy in
inoperable stage IIA or IIIB non-small-cell lung cancer: Study CTRT
99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 2006;
24:4397–4404.
15. Hanna N, NeubauerM, Ansari R, et al. Phase III trail of cisplatin (P),
plus etoposide (E), plus concurrent chest radiation (XRT) with or
without consolidation docetaxel (D) in patients with inoperable stage III
non-small cell lung cancer (NSCLC) HOG LUN01–24/USOP-023.
J Clin Oncol 2008;26:5755–5760.
16. Senan S, De Ruysscher D, Giraud P, et al. Literature-based recommen-
dations for treatment planning and execution in high-dose radiotherapy
for lung cancer. Radiother Oncol 2004;71:139–146.
17. Emani B, Perez CA, Herskovich, et al. Phase I/II of treatment of locally
advanced (t3–T4) non-oat cell lung cancer with high dose radiotherapy
(rapid fractionation). Int J Radiat Oncol Biol Phys 1988;15:1021–1025.
18. Sun L-M, Wan Leung S, Wang CJ, et al. Concomitant boost radiation
therapy for inoperable non-small-cell lung cancer: preliminary report of
a prospective randomized study. Int J Radiation Oncol Biol Phys
2000;47:413–418.
19. Saunders M, Dische S, Barret A, et al. Continuous hyperfractionated
accelerated radiotherapy (CHART) versus conventional radiotherapy in
non-small cell lung cancer: a randomized multicentre trial. CHART
Steering Committee. Lancet 1997;350:161–165.
20. Belani CP, Wang W, Jonson DH, et al. Phase III study of the Eastern
Cooperative Oncology Group (ECOG 2597): induction chemotherapy
Casas et al. Journal of Thoracic Oncology • Volume 6, Number 1, January 2011
Copyright © 2010 by the International Association for the Study of Lung Cancer84
followed by either standard thoracic radiotherapy or hyperfraction-
ated accelerated radiotherapy for patients with unresectable stage
IIIA and IIIB non-small-cell lung cancer. J Clin Oncol 2005;23:
3760 –3767.
21. Liao Z, Komaki R, Stevens C, et al. Twice daily irradiation increases
locoregional control in patients with medically inoperable or surgically
unresectable stage II-IIIB non-small-cell lung cancer. Int J Radiat Oncol
Biol Phys 2002;53:558–565.
22. Schaake-Koning C, van der Bogaert W, Dalesio O, et al. Effects of
concomitant cisplatin and radiotherapy on inoperable non-small–cell
lung cancer. N Engl J Med 1992;326:524–530.
23. Jeremic B, Shibamoto Y, Acimovic L, et al. Randomized trial of
hyperfractionated radiation therapy with or without concurrent chemo-
therapy for stage III non-small-cell lung cancer. J Clin Oncol 1995;13:
452–458.
24. Casas F, Vin˜olas N. Toxicity of small cell lung cancer treatment.
Hematol Oncol Clin N Am 2004;18:461–481.
25. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after
concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer:
phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;
21:2004–2010.
26. Glynne-Jones R, Hoskin P. Neoadjuvant cisplatin chemotherapy before
chemoradiation: a flawed paradigm? J Clin Oncol 2007;25:5281–5286.
27. Godivan R, Bogart J, Vokes EE. Locally advanced non-small cell
lung cancer: the past, present, and future. J Thorac Oncol 2008;3:
917–928.
Journal of Thoracic Oncology • Volume 6, Number 1, January 2011 Combined Modality Treatment of Stage III NSCLC
Copyright © 2010 by the International Association for the Study of Lung Cancer 85
